Spyre Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire

02/25

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit – Miami
Date: Tuesday, March 10, 2026

Members of the Spyre management team will host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at www.spyre.com.

For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614726643"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614726643\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614726643?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614726643","market":"hk","top_or_hot":-1,"title":"Spyre Therapeutics to Participate in Upcoming March Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a>, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong>Event: TD Cowen 46th Annual Health Care Conference - Boston</strong><br/><strong>Date: </strong>Tuesday, March 3, 2026<br/><strong>Presentation and Fireside Time: </strong>3:10 pm ET</p> <p><strong>Event: Leerink Global Healthcare Conference – Miami</strong><br/><strong>Date: </strong>Monday, March 9, 2026<br/><strong>Fireside Time: </strong>8:40 am ET</p> <p><strong>Event: Jefferies Biotech on the Beach <a href=\"https://laohu8.com/S/SMMT\">Summit</a> – Miami</strong><br/><strong>Date: </strong>Tuesday, March 10, 2026</p> <p>Members of the Spyre management team will host one-on-one investor meetings during the conferences.</p> <p>Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.</p> <p><strong>About Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong></p> <p>Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p> <p>For more information, visit Spyre's website at www.spyre.com.</p> <p><strong>For Investors:</strong>      <br/>Eric McIntyre, Spyre Therapeutics<br/>SVP of Finance and Investor Relations<br/>Eric.mcintyre@spyre.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZjQ0MWQ0OTgtNTIwOC00ODJjLTg0YTItODI3MWRlMjBkZTcyLTEzMDYzNjMtMjAyNi0wMi0yNC1lbg==/tiny/Spyre-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics to Participate in Upcoming March Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics to Participate in Upcoming March Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2026-02-25 05:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a>, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong>Event: TD Cowen 46th Annual Health Care Conference - Boston</strong><br/><strong>Date: </strong>Tuesday, March 3, 2026<br/><strong>Presentation and Fireside Time: </strong>3:10 pm ET</p> <p><strong>Event: Leerink Global Healthcare Conference – Miami</strong><br/><strong>Date: </strong>Monday, March 9, 2026<br/><strong>Fireside Time: </strong>8:40 am ET</p> <p><strong>Event: Jefferies Biotech on the Beach <a href=\"https://laohu8.com/S/SMMT\">Summit</a> – Miami</strong><br/><strong>Date: </strong>Tuesday, March 10, 2026</p> <p>Members of the Spyre management team will host one-on-one investor meetings during the conferences.</p> <p>Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.</p> <p><strong>About Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong></p> <p>Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p> <p>For more information, visit Spyre's website at www.spyre.com.</p> <p><strong>For Investors:</strong>      <br/>Eric McIntyre, Spyre Therapeutics<br/>SVP of Finance and Investor Relations<br/>Eric.mcintyre@spyre.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZjQ0MWQ0OTgtNTIwOC00ODJjLTg0YTItODI3MWRlMjBkZTcyLTEzMDYzNjMtMjAyNi0wMi0yNC1lbg==/tiny/Spyre-Therapeutics-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3244017/0/en/Spyre-Therapeutics-to-Participate-in-Upcoming-March-Investor-Conferences.html","article_id":"2614726643","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614726643","pubTimestamp":1771967100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redef","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4539":"次新股","SYRE":"SPYRE THERAPEUTICS INC","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Spyre Therapeutics将参加即将举行的3月份投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"SYRE":1},"content_text":"WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: TD Cowen 46th Annual Health Care Conference - BostonDate: Tuesday, March 3, 2026Presentation and Fireside Time: 3:10 pm ET Event: Leerink Global Healthcare Conference – MiamiDate: Monday, March 9, 2026Fireside Time: 8:40 am ET Event: Jefferies Biotech on the Beach Summit – MiamiDate: Tuesday, March 10, 2026 Members of the Spyre management team will host one-on-one investor meetings during the conferences. Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com. For Investors:      Eric McIntyre, Spyre TherapeuticsSVP of Finance and Investor RelationsEric.mcintyre@spyre.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}